VEMZATATUG VEDOTIN
UNII QV6BNJ79VJ

Substance Identification & Data

This profile provides standardized clinical and technical data for Vemzatatug Vedotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) QV6BNJ79VJ.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3035714-53-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

QV6BNJ79VJ

CAS Registry Number

3035714-53-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

VEMZATATUG VEDOTIN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C217729

National Cancer Institute reference terminology for clinical and research data.

INN ID

13665

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-192

Identifier assigned by the United States Adopted Names Council.

Substance Type

Vemzatatug Vedotin

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Vemzatatug Vedotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Vemzatatug Vedotin

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-454) [VH (Homo sapiens IGHV3-7*01 (86.0%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.10.15] (26-33.51-60.99-113)) (1-124) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 D12 (363), L14 (365) (348-452), CHS (453-454)) (125-454)], (227-214')-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (89.5%) -IGKJ2*02 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (233-233'':236-236'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of an average of four L-cysteinyl residues among 227, 233, 236, 214', 227'', 233'', 236'' and 214''' with (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin) groups

Immunoglobulin G1, anti-(human G protein-coupled receptor GPRC5D) (human-Mus musculus monoclonal INT-026 γ1-chain), disulfide with human-Mus musculus monoclonal INT-026 κ-chain, dimer, reduced, thioether with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide

VEMZATATUG VEDOTIN [USAN]

immunoglobulin G1-kappa, anti-[Homo sapiens GPRC5D (G protein-coupled receptor class C group 5 member D)], humanized monoclonal antibody; conjugated on an average of four cysteinyl residues to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE) (vemzatatug vedotin)

vemzatatug vedotin [INN]

Technical Codes

AZD0305

External Clinical & Regulatory Resources

Previous UNIIQV6353F6TG

Next UNIIQV6QP4MX2V